Coronary stents

2025: System released to quickly install cardiac stents instead of long, risky surgeries

On January 23, 2025, Vantis Vascular announced the release of the integrated CrossFAST delivery system designed to quickly install cardiac stents. The solution eliminates the need for long and risky operations. Read more here.

2024

Global Coronary Stent Market Growth to $6.68 Billion

At the end of 2024, the costs of the global coronary stent market reached $6.68 billion. About a third of this amount fell on the North American region. This is stated in a study by Fortune Business Insights, the results of which were released on March 26, 2025.

Coronary stents are medical devices that are a frame in the form of a metal cylinder. They are placed in bottlenecks in the arteries to expand them in order to normalize blood flow. Stents allow you to fight stenosis of arterial vessels arising from the deposition of atherosclerotic plaques. Stents are often used in the treatment of acute myocardial infarction, occlusion of the mouth or trunk of the left main coronary artery, chronic total vascular occlusion, etc.

One of the main drivers of the industry in question, analysts name the wide prevalence of cardiovascular diseases, including coronary heart disease. Such ailments, according to the World Health Organization (WHO), are the leading cause of death in the world. In particular, in the European region, cardiovascular diseases account for more than 42.5% of all deaths: this means that about 10 thousand people die from them every day. Heart attacks and strokes are usually acute diseases and occur mainly as a result of blockage of blood vessels, which prevents blood from flowing to the heart or brain. The most common reason for this is the formation of fat deposits on the inner walls of the blood vessels that supply blood to the heart or brain. In many such cases, stenting is an effective and safe procedure.

Technological advances play an important role in the development of the market, as noted in the report. Improvements in stenting procedures reduce errors during operations. This contributes to the wider use of the products among cardiologists in both developed and developing countries. The advantages of the method include minimally invasive (the patient can quickly return to his usual lifestyle), high treatment efficiency and manufacturability (during the operation, exclusively modern equipment and innovative expensive materials are used). However, the high cost of stenting procedures, especially in developing regions, may limit their availability.

Depending on the type of products, the market is segmented into drug-eluting stents, holometallic stents, fully soluble biodegradable scaffolds, etc. According to estimates, in 2024, the lion's share of revenue was provided by the first type of products - approximately 76%. In terms of the base material for stents (metal and polymer), metal-based articles dominate. From a geographical point of view, North America leads, which in 2024 accounted for $2.21 billion. However, a year earlier, spending in this region was higher - $2.8 billion. Significant players in the global market are:

• Medtronic;
• Boston Scientific;
• Biotronik SE & Co. KG№
• Terumo Corporation;
• Abbott;
• Relisys Medical Devices Limited;
• Braun SE;
• MicroPort Scientific Corporation;
• Stentys S.A.;
• Meril Life Sciences Pvt.

In 2025, spending on coronary stents worldwide is expected to reach $7.02 billion. Fortune Business Insights analysts believe that in the future, the CAGR will be 6.2%. As a result, by 2032, costs on a global scale could increase to $10.66 billion.^[1]

A carotid artery stent was released and began to be installed. It prevents strokes

In early October 2024, the company InspireMD received permission to study stentings the carotid artery system CGuard Prime 80 cm to prevent embolization of the brain brain and development. stroke More here

2022

Medtronic starts selling stent for patients with coronary heart disease

On August 25, 2022, Medtronic announced the launch of its new Onyx Frontier DES coronary stent, which is used to treat patients with coronary heart disease caused by a build-up of plaques on the inner surface of the coronary arteries. Read more here.

Russian medical production of stents for cores threatened due to attack by raiders

In June 2022, it became known that Angiolaine had stopped the production of medical devices for cardiac surgery. The company explained the termination of production "certain disagreements between shareholders." Read more here.

2021: Medtronic and Renova joint venture launches production of Translumina coronary stents in Skolkovo

The Russian company Stentex, which transfers the technologies for the production of coronary stents and catheters necessary for the treatment of myocardial infarction and unstable angina, will produce Sirolimus drug-coated coronary stent systems under the Yukon Choice PC and Yukon Chrome PC brand, which are developed by the German-Indian company Translumina. This became known at the end of July 2021. Read more here.

2019

Ministry of Health decided to digitally label diapers and coronary stents

In December 2019, it became about the digital labeling of medical devices planned by the Government of the Russian Federation. From February 1, 2020 to September 1, 2021, it is planned to conduct a pilot project to control the supply of diapers and coronary stents. Read more here.

Stents in the heart are no better than drugs

In mid-November 2019, the results of a global study were published, which showed that in many patients with severe but stable coronary heart disease, regular medication and a healthy lifestyle prevent heart attack and death from heart disease no less effectively than invasive procedures with stent placement.

A government-supported study questioned the concept that invasive procedures to restore normal blood flow in patients with stable coronary heart disease are more effective than conservative treatment with aspirin, lipid-lowering and antihypertensive agents. Scientists have concluded that stenting or bypass grafting is far from always necessary for a patient with a stable disease. According to experts, many cardiologists do not want to change their tactics in part because patients with stents usually feel relief quickly, while with conservative therapy, changes occur gradually, and the patient barely feels them.

Medication and a healthy lifestyle prevent heart attack and death from heart disease no less effectively than invasive procedures with stent placement.

For those who experience little or no chest pain, immediate stenting will play no role... But with myocardial infarction, stents save lives.

The study covered 37 countries and included 5179 participants with moderate to severe but stable cardiac ischemia. Half of the participants received only drugs and lifestyle recommendations over a four-year period, while the other half underwent surgeries in addition to drug therapy. More than $100 million was spent on the study.^[2]

Medtronic and Boston Scientific continue to sell stents that are dangerous to humans

At the beginning of January 2019, Medtronic and Boston Scientific continue to sell stents coated with paclitaxel, despite the fact that a month earlier a study was published indicating an association between the use of devices and an increased mortality rate. Read more here.

2017: Lower bench prices in India

In mid-September 2017, it became known about a significant decrease in prices for coronary stents in India, which had a positive effect on the business of local manufacturers, which cannot be said about foreign companies such as Medtronic and Abbott.

According to The Economic Times (ET), the Indian government has reduced the maximum cost of stents by more than 80%. This has led to increased sales of equipment from local vendors including Sahajanand Medical Technologies (SMT), Translumina Therapeutics and Meril Life Sciences, which jointly control about 30% of the Indian stent market.

Coronary stent

Thanks to restrictive measures of the authorities, local manufacturers expect to occupy 60% of the market in 2017, the volume of which, however, can be reduced to 12 billion rupees ($187.3 million) from 15 billion rupees (about $234 million) in 2016. This decline will be the result of cheaper products, Rajiv Nath, coordinator of the Association of Indian Medical Device Industry (AiMeD), told ET.

He did not disclose the dynamics of stent sales after changing the price threshold. Sources of the publication speak of a rise of 30-50%.

At the end of 2017, SMT, Translumina and Meril expect to bring their share in the Indian coronary stent market to 35% due to "confusion and panic," which appeared after international companies were forced to curtail sales of new products in the country, said the head of one of the mentioned Indian companies.

Abbott said that the reduction in maximum prices prevents the company from selling new stents in India, since their cost is higher than the prices at which devices can be sold. Medtronic and Boston Scientific have also approached Indian pharmaceutical market regulator NPPA over the recall of new products.^[3]